Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
William G. Kaelin, MD
Dana-Farber physician-scientist William G. Kaelin, MD,
is one of five recipients of a 2010 Canada Gairdner Award, among the
world's most prestigious medical research honors. The announcement came
this morning in Toronto.
Kaelin and two other scientists working independently are sharing a
Canada Gairdner International Award for identifying the molecular
mechanisms that allow cells to detect a shortage of oxygen and respond
by making new red blood cells and blood vessels.
The research may pave the way for therapies that manipulate oxygen to
treat diseases ranging from heart disease and anemia to cancer.
"I am very happy and proud, and this is a very nice recognition of
the people who have done excellent work in the lab over the years," says
Kaelin. "Having your peers and people whom you admire appreciate the
quality of your work is a wonderful experience."
Kaelin, who is a member of the Department of Medical Oncology, became
an independent investigator at Dana-Farber in 1992, and has been an
investigator of the Howard Hughes Medical Institute since 1998.
"Bill has made groundbreaking discoveries that have transformed our
understanding of many forms of cancer," says Dana-Farber President Edward J. Benz Jr., MD. "His work has also pointed the way to new
strategies to find better therapies for these tumors. He is very
deserving of this recognition and has also brought honor to
Kaelin was elected in 2007 to the Institute of Medicine, a
non-governmental body that gives advice on health and science policy.
Members are elected based on their distinguished and continuing
achievements in original research. In 2001 he won a Paul Marks Prize for
Cancer Research from Memorial Sloan-Kettering Cancer Center.
The Canada Gairdner Awards were established in 1959 to recognize and
reward researchers whose work contributes significantly to improving the
quality of human life. Nearly one-quarter of past recipients have gone
on to win a Nobel Prize.
The awards, which include a $100,000 cash prize, will be presented in
October to the seven recipients. The co-recipients, along with Kaelin,
are Gregg L. Semenza, MD, PhD, of Johns Hopkins University School of
Medicine and Peter J. Ratcliffe, MD, of the University of Oxford. A
total of five scientists received 2010 Gairdner International Awards.
Tumor suppressor genes, so called because they help to prevent normal
cells from becoming cancerous, have long been a research focus in the
Kaelin lab. Mutations in tumor suppressor genes are a cause of many
types of cancer. Kaelin's long-term goal is to lay the foundation for
the development of new anticancer therapies based on understanding the
normal functions of such genes.
Kaelin and his colleagues have been studying von Hippel Lindau
syndrome, a rare disorder caused by a mutation in a tumor suppressor
gene that makes patients likely to develop kidney cancer.
Kaelin found that the tumor suppressor gene mutation causes kidney
tumors to churn out large amounts of a protein, VEGF, which helps
provide the tumors with an extra blood supply to fuel the cancer's
Essentially, the mutation causes the tumor cells to behave as if they
were starved of oxygen, which spurs the overproduction of VEGF to
recruit new blood vessels to nourish the tumor.
Kaelin's work, along with that of his two co-awardees, showed that
this process is regulated by a protein called Hypoxia-inducible factor
1-alpha. Manipulating this factor with drugs is currently being
investigated as potential treatments for anemia, heart attacks, strokes,